ENVISIONING AN END TO NEURODEGENERATIVE DISEASES
ENVISIONING AN END TO NEURODEGENERATIVE DISEASES
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules to accelerate the identification of therapeutics
Our approach
Our Lead Program
Our Lead Program
Mechanistic Rationale
Mechanistic Rationale
Supporting Literature
Supporting Literature

Therapeutic Development
Our brain-penetrant small molecules inhibit HDAC6, an enzyme that modifies key proteins involved in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) pathology. Inhibiting HDAC6 will preserve axonal transport and stop or slow the progression of ALS and also help neuron health in other neurodegenerative disease. Emerging data suggest HDAC6 inhibition could also prevent pathological tau phosphorylation and downstream aggregation (tangles) in AD and ‘chemo-brain’.
De-risk therapeutic approaches to neurodegeneration
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.
HDAC6 inhibitor treatment will preserve axonal transport and stop or slow the progression of AD and ALS